3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Liver Failure
1
Leukemia-Lymphoma, Adult T-Cell
1
Hepatitis C
1
Hepatitis B
1
Hepatic Insufficiency
1
Head and Neck Neoplasms
1
HIV Infections
1
Carcinoma, Hepatocellular
1
Interventions
Ribavirin
4
ledipasvir, sofosbuvir drug combination
3
sofosbuvir-velpatasvir drug combination
2
elbasvir-grazoprevir drug combination
2
Sorafenib
2
Sofosbuvir
2
telaprevir
1
rocakinogene sifuplasmid
1
pembrolizumab
1
peginterferon alfa-2a
1
navitoclax
1
menatetrenone
1
ledipasvir
1
hepatitis C immune globulin, human
1
grazoprevir
1
elbasvir
1
Rapid Diagnostic Tests
1
Raltegravir Potassium
1
Patient Navigation
1
Medical Marijuana
1
Mass Screening
1
Introns
1
Immunoglobulin G
1
Immunoenzyme Techniques
1
Hypothermia, Induced
1
Enzyme-Linked Immunosorbent Assay
1
Chromatography, High Pressure Liquid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Hepatitis C
×
Raltegravir Potassium
×
Clear all
NCT01022476
2026-04-06
LIVERAL
ANRS, Emerging Infectious Diseases
Phase 1/2
Completed
14 enrolled